×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Viva Biotech Announces Share Option Schemes - TipRanks.com
Tipranks
Viva Biotech Holdings (HK:1873) has released an update. Viva Biotech Holdings has successfully adopted its Viva Shanghai Phase I and Phase II Share Option...
5 days ago
Viva Biotech Holdings' (HKG:1873) market cap up HK$193m last week, benefiting both individual investors who own 45% as well as insiders
Simply Wall Street
A look at the shareholders of Viva Biotech Holdings (HKG:1873) can tell us which group is most powerful. And the group that holds the biggest...
2 months ago
Viva Biotech Secures Approx. US$ 210M Funding
FinSMEs
Viva Biotech (01873.HK), a Hong Kong-based provider of services ranging from early-stage structure-based drug R&D to commercial drug...
6 months ago
Latest biotech news: fundraises, deals, clinical trials | Nov 24, 2023
Labiotech.eu
Here is Labiotech's weekly roundup of the latest biotech news. Whether it is partnerships, clinical trials, or fundraising, we have got you...
6 months ago
Temasek-backed firms buy stake in VIVA Biotech unit ahead of listing
Reuters
June 12 (Reuters) - Entities backed by Singapore's Temasek and Chinese investment firm HighLight Capital agreed to a deal worth 1.06 billion...
11 months ago
Viva Biotech Advances CRO, CDMO Products, Secures $210M Investment
Contract Pharma
Viva Biotech Holdings Group reported that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearly $150...
11 months ago
Firms backed by Temasek, HighLight Capital buy stake in Viva Biotech unit ahead of listing
The Straits Times
VIVA Biotech said it will use the net proceeds to redeem convertible bonds. Read more at straitstimes.com.
11 months ago
DTx Pharma Completes $100M Series B Financing to Advance its FALCON™ Platform and Pipeline of RNA Therapeutics
PR Newswire
PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic...
39 months ago
Novartis Acquires DTx Pharma, for Approx. USD1 Billion
FinSMEs
Novartis acquired DTx Pharma, a San Diego, CA-based biotechnology company, for approx. $1 Billion. Novartis will make an upfront payment of...
10 months ago
How to make big money from early stage biotechs
The Australian
Andrew Wilks – the scientist who discovered a molecule that pharmaceutical titan GSK bought for $1.9bn last year – is launching his own...
9 months ago